24/7 Emergency & General Advisory
🚨 24/7 Medical Emergency
Non-Emergency Advisory
10:00 AM – 6:00 PM, Mon–Sat
For appointments & general queries.
Join our healthcare community
Stay updated with our latest healthcare news and your appointments.
HIV testing is the only reliable way to know your HIV status. Modern tests can detect infection earlier than older antibody-only tests, but every test has a window period. For people who are HIV-negative and have a substantial risk of acquiring HIV,
An HIV test looks for evidence of HIV infection in the blood or another sample, depending on the test used.
Testing matters because HIV can remain without obvious symptoms for years. A person can feel completely healthy and still have HIV and potentially transmit it.
HIV testing is also the first step in prevention. If a person tests positive, effective HIV treatment can protect their health and prevent sexual transmission when viral suppression is maintained.
For people who test negative but have ongoing exposure risk, prevention options such as condoms and PrEP can reduce the chance of acquiring HIV.
Doctar's STI testing guide provides broader information about sexual-health testing.
HIV tests generally look for antibodies, HIV antigen, or the virus itself.
These tests detect antibodies produced by the immune system after HIV infection.
They can be convenient and are available in some rapid and self-testing formats, but they generally take longer to become positive than tests that detect antigen as well.
These tests look for both HIV antibodies and p24 antigen, a viral protein that appears earlier in infection.
Laboratory fourth-generation antigen-antibody tests are widely used because they can detect HIV earlier than antibody-only testing.
Nucleic acid testing, sometimes called an HIV RNA or NAT test, looks directly for HIV genetic material.
It may detect infection earlier than antibody or antigen-antibody testing but is not routinely required for every screening situation.
The exact test available depends on the healthcare setting and country.
A window period is the time between HIV exposure and when a particular test can reliably detect infection.
This is one of the most important things to understand about HIV testing.
A negative test immediately after a possible exposure cannot necessarily rule out HIV. Different tests have different detection windows, so the appropriate time for repeat testing depends on the test used and the timing of exposure.
If you recently had a possible exposure, tell the healthcare professional when it happened and what type of exposure occurred. That information helps determine which test and follow-up schedule are appropriate.
HIV self-testing is available in many settings.
A self-test can make testing more private and accessible, but a reactive result needs confirmatory testing through a healthcare service. A non-reactive result may also need to be repeated if testing occurred during the window period.
WHO's current HIV guidance supports flexible testing approaches, including rapid testing in the context of long-acting PrEP.
Doctar's free STI testing guide discusses accessible testing options.
PrEP stands for pre-exposure prophylaxis.
It involves using antiretroviral medicine by people who are HIV-negative to reduce their risk of acquiring HIV.
WHO recommends PrEP as an additional prevention choice for people at substantial risk of HIV infection. It should form part of a broader prevention approach rather than replace other effective measures.
PrEP is not a vaccine and does not permanently protect someone after one dose. Different PrEP products have different schedules and eligibility requirements.
PrEP can be highly effective at preventing HIV when used correctly and consistently. WHO describes oral PrEP as highly effective when used as directed.
Effectiveness depends on the medication, dosing approach, adherence and type of sexual exposure.
This is why PrEP should be prescribed and monitored by a healthcare professional rather than treated like an ordinary over-the-counter supplement.
PrEP may be appropriate for an HIV-negative person who has a substantial ongoing risk of acquiring HIV.
Risk can vary according to:
whether a sexual partner has HIV and their treatment status
condom use
number or type of sexual partners
recent STI history
local HIV prevalence
sexual practices
injecting-drug exposure
whether a partner's HIV status is unknown
There is no single “PrEP person.”
A doctor can help determine whether PrEP fits your circumstances.
HIV infection should be ruled out before starting PrEP.
This is important because PrEP uses antiretroviral medicines, and someone who already has HIV needs a complete treatment regimen rather than PrEP alone.
WHO guidance recommends HIV testing when PrEP is initiated and continued, with testing approaches adapted to the type of PrEP being used.
Depending on the PrEP product and clinical situation, healthcare providers may also assess kidney function, hepatitis status and other health factors.
No.
PrEP protects against HIV, not chlamydia, gonorrhea, syphilis, herpes or HPV.
That is why combination prevention remains important.
Condoms can reduce the risk of HIV and several other STIs, while vaccination can prevent infections such as HPV and hepatitis B in eligible people.
Doctar's STI prevention guide covers these additional prevention measures.
PrEP is taken before potential exposure.
PEP, or post-exposure prophylaxis, is used after a possible HIV exposure.
PEP is time-sensitive. WHO's 2024 guidance says it is most effective when started as soon as possible, ideally within 24 hours, and no later than 72 hours after exposure. A recommended course is taken for 28 days.
If you think you have had a significant HIV exposure within the past 72 hours, don't wait for symptoms or a routine appointment. Seek urgent medical advice about PEP.
Do not start or borrow someone else's HIV medication.
PrEP | PEP | |
|---|---|---|
Meaning | Pre-exposure prophylaxis | Post-exposure prophylaxis |
Timing | Before potential exposure | After potential exposure |
Purpose | Prevent HIV acquisition | Prevent HIV after a possible exposure |
Use | Planned prevention | Time-sensitive emergency prevention |
Medical assessment | Required | Urgent assessment required |
The two strategies are complementary, not interchangeable.
Yes.
WHO recommends PrEP as part of combination HIV prevention, and condoms remain an established tool for preventing HIV and other STIs.
Some people use PrEP because condoms are not always practical or consistently used. Others use both.
The right prevention strategy is the one that can be used consistently and safely.
PrEP is no longer limited to daily oral medication.
WHO has recommended long-acting injectable cabotegravir as an additional PrEP choice and, in 2025, added twice-yearly injectable lenacapavir to its recommended HIV prevention options.
Availability varies by country and healthcare system.
These newer options may be particularly useful for people who find daily pills difficult to take consistently, but they still require appropriate HIV testing and clinical follow-up.
PrEP should not simply be started without establishing that the person is HIV-negative.
This is especially important if there has been a recent exposure or symptoms that could represent acute HIV infection.
WHO guidance emphasises HIV testing when initiating and continuing PrEP.
A healthcare professional can decide whether additional testing is needed when recent exposure makes the result difficult to interpret.
Yes.
PrEP is a medical prevention strategy rather than a one-time treatment.
Follow-up generally includes ongoing HIV testing and assessment of the person's continued need for PrEP. Depending on the medication, clinicians may also monitor kidney function and other relevant health factors.
WHO's PrEP implementation guidance includes HIV, kidney and STI assessment as part of PrEP services.
The exact monitoring schedule depends on the product and national guidance.
PrEP medicines can cause side effects, although many people tolerate them well.
Potential effects vary according to the medication. Some oral tenofovir-based PrEP regimens can affect kidney function or bone mineral density in susceptible people, which is one reason clinical assessment and monitoring may be recommended.
Long-acting products have their own safety considerations.
Don't stop or change PrEP because of a side effect without discussing it with the prescribing clinician.
PrEP does not necessarily have to be lifelong.
A person's HIV exposure risk can change with relationships, sexual activity, partners and other circumstances. WHO describes PrEP as an individual prevention choice that may be used during periods of increased risk.
However, stopping PrEP needs to be discussed with a healthcare professional because protection does not disappear in exactly the same way for every product or dosing approach.
A positive screening result is not the same as a final diagnosis.
Confirmatory testing is required according to the testing algorithm used by the healthcare service.
If HIV infection is confirmed, effective antiretroviral treatment can suppress the virus. Modern HIV treatment has transformed HIV from a condition that was once frequently fatal into a manageable chronic infection for people who can access and maintain treatment.
People who achieve and maintain an undetectable viral load through effective treatment do not sexually transmit HIV. This is commonly summarised as U=U, undetectable equals untransmittable.
For many people, yes.
HIV can remain asymptomatic for a long time. Testing can provide reassurance when negative and allow early treatment when positive.
Testing may be particularly relevant after:
condomless sex with a new or unknown-status partner
a partner testing positive for HIV
another STI diagnosis
sharing injection equipment
sexual exposure in a setting with higher HIV prevalence
a potential occupational or non-occupational exposure
Doctar's HIV and urinary-system guide provides additional HIV-related information.
PrEP users may benefit from regular STI screening because PrEP prevents HIV but does not prevent other sexually transmitted infections.
Depending on sexual practices and exposure, testing may include chlamydia, gonorrhea and syphilis.
For men with symptoms such as discharge, genital sores or painful urination, testing should be based on the affected body site and clinical assessment.
Doctar's chlamydia and gonorrhea guide explains common symptoms and testing.
If the exposure happened within the previous 72 hours, PEP may be an option.
Do not wait for an HIV test result if doing so would delay access to PEP. A clinician can assess the exposure and decide whether PEP is appropriate.
WHO specifically emphasises that starting PEP as quickly as possible is critical.
This is one situation where timing really matters.
HIV prevention works best as a combination of strategies.
Useful measures include:
regular HIV testing
PrEP when clinically appropriate
condoms and compatible lubricants
prompt STI testing and treatment
avoiding shared needles or injection equipment
HIV treatment for people living with HIV
PEP after eligible recent exposures
hepatitis B and HPV vaccination when appropriate
There is no need to choose prevention based on shame or fear. The goal is to find an approach that fits real life and can be used consistently.
In clinical practice, people sometimes think an HIV test is only necessary when symptoms appear. That misses the central point of HIV screening: infection can be present without obvious symptoms.
Visit Hospital
Near You
Find verified endocrinologists in Lucknow on DOCTAR. Compare experience, ratings, consultation fees and hospital locations, then book an appointment online.
August 22, 2026
Hormonal problems can affect weight, blood sugar, periods, energy levels, growth and several other parts of health. A hormone specialist, usually an endocrinologist, evaluates conditions involving the body's hormone-producing glands.
August 22, 2026
Find and book verified family doctors (general physicians) in Kolkata. Compare 327 doctors by fees (₹200–₹1,500), experience, ratings and hospital affiliation. Same-day appointments available with 316 doctors. Consultations in English, Hindi and Bengali.
August 22, 2026